3⃣🚀Session Three has just started at #ACC2026
The focus turns to preclinical antimicrobial development, with talks exploring lysin biotherapeutics, anti-virulence approaches and new adjunct therapies to tackle drug-resistant infections.
🎥 Join us now: portalapp.bsac.eventsair.com/VirtualAtten... Dr Christopher Jonkergouw:
"Combining dual-acting extracellular anti-virulence inhibitors with antibiotics is a powerful strategy to tackle resistance effectively without competing with the current antibiotics."🦠🔬
🎥 The Q&A is live right now: portalapp.bsac.eventsair.com/VirtualAtten...
#ACC2026 🔚The session comes to a close
Insightful talks and lively discussion highlighted promising preclinical approaches to tackling #AMR.
We’ll move into the final session of the day shortly.
#ACC2026 
